The Cardiac Autonomic Control Market Size is valued at USD 15.69 Bn in 2022 and is predicted to reach USD 29.31 Bn by the year 2031 at a 7.3% CAGR during the forecast period for 2023-2031.
Cardiac autonomic control, the market for non-invasive devices and technology to control autonomic nervous system functions to manage cardiovascular disorders, including heart rate and blood pressure, is known as the cardiac autonomic control market. Hence, blocking this step can halt the virus's propagation. Heart failure, cardiac arrhythmias, and other cardiovascular illnesses are monitored and treated by cardiac autonomic control devices. The growing number of people suffering from conditions including hypertension, arrhythmias, and heart failure has increased the need for effective methods of cardiac autonomic regulation.
The autonomic nervous system, which controls the cardiovascular system, is the target of these technologies designed to monitor and control it. This trend is expected to fuel the need for cardiac autonomic control devices. Increasing demand for patients more likely to seek treatment for heart issues now that a greater emphasis on monitoring and treating cardiovascular health drives expansion globally and is expected to boost the market expansion in the coming years.
However, the population growth of patients and obtaining the necessary clearances from regulators could prove difficult for the cardiac autonomic control business during the COVID-19 outbreak. It may restrain the development of the target market over the predicted time frame. As a result of the global spread of COVID-19, international trade in medical supplies has been disrupted. The pandemic has hampered the expansion of this market because of the uncertainty and interruption in the availability of medications. Furthermore, increasing R&D activities and investments by prominent players are expected to create lucrative growth opportunities in revenue for players operating in the global cardiac autonomic control market over the forecast period.
Competitive Landscape
Some major key players in the Cardiac Autonomic Control Market:
- Medtronic plc
- Abbott Laboratories
- Boston Scientific Corporation
- Biotronik SE & Co. KG
- MicroPort Scientific Corporation
- LivaNova PLC
- Nihon Kohden Corporation
- Schiller AG
- Johnson & Johnson
- GE Healthcare
Market Segmentation:
The cardiac autonomic control market is segmented based on product type, application, and end-user. As per the product type, the market is segmented into implantable cardiac and external cardiac autonomic control devices. By application, the market is segmented into heart rate control, blood pressure control, arrhythmia control, and others. Lastly the end-user, the market is segmented into hospitals and clinics, ambulatory surgical centres, research institutes, and others.
Based On Product Type, The Implantable Cardiac Autonomic Control Devices Segment Is Accounted As A Major Contributor To The Cardiac Autonomic Control Market
The implantable cardiac autonomic control devices category is expected to hold a major share of the global cardiac autonomic control market in 2022. It is attributed to an increase in heart-related issues. The market is expanding due to increasing demand for people with certain heart rhythm abnormalities and heart failure who may benefit from using cardiac implantable electronic devices such as pacemakers, cardioverter defibrillator biventricular pacemakers, and cardiac loop recorders. Thus, the system closely monitors your pulse and helps you return to a regular pace. Additionally, the constant developments in healthcare technology have led to the creation of novel tools like implantable sensors, remote monitoring systems, and wearable devices.
The Hospitals And Clinics Segment Witnessed Development At A Rapid Rate
The segment of hospitals and clinics is projected to rise at a rapid rate in the global cardiac autonomic control market owing to an increase in the number of people seeking heart disease medical attention and the need for cardiac autonomic control devices, especially in countries such as the US, Germany, UK, China, and India.
In The Region, The North American Cardiac Autonomic Control Market Holds A Significant Revenue Share.
The North American cardiac autonomic control market is estimated to record the maximum market share in revenue in the near future. It can be attributed to the increased rates of cardiovascular illness, improved awareness of the significance of autonomic control of the heart, and increasing financing for cardiovascular research have all contributed to this trend. The existence of major players providing novel heart medications for treating heart failure or low heart rate would also contribute to the expansion of the market. Growing demand for cardiac treatment medications across industries contributes to the expansion of the industry in the region.
In addition, Asia Pacific is likely to grow rapidly in the global cardiac autonomic control market because there are more options for care and growing financial support from the business and medical communities.
Cardiac Autonomic Control Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 15.69 Bn |
|
Revenue Forecast In 2031 |
USD 29.31 Bn |
|
Growth Rate CAGR |
CAGR of 7.3% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product Type, Application, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, MicroPort Scientific Corporation, LivaNova PLC, Nihon Kohden Corporation, Schiller AG, Johnson & Johnson, GE Healthcare |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
